Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
To explore the objective response rate and safety of toripalimab combined with Gemox in the
first-line treatment of progressive, metastatic or unresectable advanced ICC.